Literature DB >> 19429976

Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.

P J Dickinson1, E I Surace, M Cambell, R J Higgins, C M Leutenegger, A W Bollen, R A LeCouteur, D H Gutmann.   

Abstract

Meningiomas are common primary brain tumors in dogs; however, little is known about the molecular genetic mechanisms involved in their tumorigenesis. Several tumor suppressor genes have been implicated in meningioma pathogenesis in humans, including the neurofibromatosis 2 (NF2), protein 4.1B (4.1 B), and tumor suppressor in lung cancer-1 (TSLC1) genes. We investigated the expression of these tumor suppressor genes in a series of spontaneous canine meningiomas using quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) (NF2; n = 25) and western blotting (NF2/merlin, 4.1B, TSLC1; n = 30). Decreased expression of 4.1B and TSLC1 expression on western blotting was seen in 6/30 (20%) and in 15/30 (50%) tumors, respectively, with 18/30 (60%) of meningiomas having decreased or absent expression of one or both proteins. NF2 gene expression assessed by western blotting and RT-PCR varied considerably between individual tumors. Complete loss of NF2 protein on western blotting was not seen, unlike 4.1B and TSLC1. Incidence of TSLC1 abnormalities was similar to that seen in human meningiomas, while perturbation of NF2 and 4.1B appeared to be less common than reported for human tumors. No association was observed between tumor grade, subtype, or location and tumor suppressor gene expression based on western blot or RT-PCR. These results suggest that loss of these tumor suppressor genes is a frequent occurrence in canine meningiomas and may be an early event in tumorigenesis in some cases. In addition, it is likely that other, as yet unidentified, genes play an important role in canine meningioma formation and growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429976     DOI: 10.1354/vp.08-VP-0251-D-FL

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  10 in total

1.  Canine spontaneous glioma: a translational model system for convection-enhanced delivery.

Authors:  Peter J Dickinson; Richard A LeCouteur; Robert J Higgins; John R Bringas; Richard F Larson; Yoji Yamashita; Michal T Krauze; John Forsayeth; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; John W Park; Mitchel S Berger; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2010-05-20       Impact factor: 12.300

2.  Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity.

Authors:  Brian M Andersen; G Elizabeth Pluhar; Charles E Seiler; Michelle R Goulart; Karen S SantaCruz; Melissa M Schutten; Joyce P Meints; M Gerard O'Sullivan; R Timothy Bentley; Rebecca A Packer; Stephanie A Thomovsky; Annie V Chen; Dominik Faissler; Wei Chen; Matthew A Hunt; Michael R Olin; John R Ohlfest
Journal:  Cancer Res       Date:  2013-03-07       Impact factor: 12.701

3.  Tumor suppressor TSLC1 inhibits growth, proliferation, invasiveness and angiogenesis in nude mice xenografted tumor of Eca109 cells.

Authors:  Qi-Lian Liang; Guo-Qiang Chen; Qiu-Long Liu; Zhou-Yu Li; Xiang-Ning Zhang; Yuan Zhou; Wen-Ting Ou; Bi-Rong Wang; Li-Ren Hu
Journal:  Int J Clin Exp Med       Date:  2014-06-15

4.  Construction of eukaryotic expression vector of TSLC1 gene.

Authors:  Qi-Lian Liang; Bi-Rong Wang; Zhou-Yu Li; Guo-Qiang Chen; Yuan Zhou
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

5.  Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.

Authors:  Lisa J Schlein; Bahaa Fadl-Alla; Holly C Pondenis; Stéphane Lezmi; Charles G Eberhart; Amy K LeBlanc; Peter J Dickinson; Paul J Hergenrother; Timothy M Fan
Journal:  Front Oncol       Date:  2019-02-25       Impact factor: 6.244

6.  Molecular Targets and Treatment of Meningioma.

Authors:  Rickey Miller; Michele L DeCandio; Yaenette Dixon-Mah; Pierre Giglio; W Alex Vandergrift; Naren L Banik; Sunil J Patel; Abhay K Varma; Arabinda Das
Journal:  J Neurol Neurosurg       Date:  2014

Review 7.  Advances in diagnostic and treatment modalities for intracranial tumors.

Authors:  P J Dickinson
Journal:  J Vet Intern Med       Date:  2014-05-09       Impact factor: 3.333

8.  Loss of CADM1/TSLC1 Expression Is Associated with Poor Clinical Outcome in Patients with Esophageal Squamous Cell Carcinoma.

Authors:  De Zeng; Xiao Wu; Jin Zheng; Yixuan Zhuang; Jiongyu Chen; Chaoquan Hong; Fan Zhang; Mingyao Wu; Danxia Lin
Journal:  Gastroenterol Res Pract       Date:  2015-12-31       Impact factor: 2.260

9.  RNA-seq transcriptome analysis of formalin fixed, paraffin-embedded canine meningioma.

Authors:  Jennifer K Grenier; Polly A Foureman; Erica A Sloma; Andrew D Miller
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

Review 10.  Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors.

Authors:  Andrew D Miller; C Ryan Miller; John H Rossmeisl
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.